Linked Life Data

15737832

Source:http://linkedlifedata.com/resource/pubmed/id/15737832

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-3-1
pubmed:abstractText
Thymidine phosphorylase (TP) is often induced in the tumour microenvironment by physiological and chemical stress. Its induction protects cells from apoptosis and helps cell survival by stimulating nucleoside metabolism and angiogenesis. Chemotherapy often upregulates TP, which acts in cell rescue; this result indicates that TP is a crucial therapeutic target. Clinical trials for metastatic diseases have shown that TP-targeting chemotherapy with fluorouracil derivatives greatly improves the effectiveness of conventional chemotherapy for not only response but also prognosis. This new idea, the improvement of TP-inducible therapy with TP-targeting therapy, should be further investigated for early disease states, and inhibitors of TP warrant extensive investigation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1470-2045
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
158-66
pubmed:dateRevised
2006-7-7
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment.
pubmed:affiliation
Department of Clinical Trials and Research, Tokyo Metropolitan Cancer and Infectious Disease Centre, Komagome Hospital, Tokyo, Japan. maktoi77@wa2.so-net.ne.jp <maktoi77@wa2.so-net.ne.jp>
pubmed:publicationType
Journal Article, Review